Research presented at the European Atherosclerosis Society 2024 showed that the anti-obesity drug semaglutide led to significant reductions in the inflammatory marker high-sensitivity C-reactive protein (CRP) in patients with overweight or obesity, regardless of weight loss. The SELECT trial involving over 17,600 patients with cardiovascular disease found that semaglutide lowered CRP levels by 38% compared to placebo. The drug also reduced the risk of major adverse cardiovascular events. While weight loss is a major contributor to CRP levels, the study suggested that the drug’s anti-inflammatory effects may also play a role. Further research is needed to fully understand the relationship between semaglutide, inflammation, and cardiovascular outcomes in obesity.
Source link
Is Semaglutide Anti-inflammatory?
